Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Gelesis Closes $22M Equity Financing

By Drug Discovery Trends Editor | March 27, 2015

Gelesis, a clinical stage biotechnology company focused on the development of first-in-class products to induce weight loss and improve glycemic control, announced today that it closed an equity financing of shares of convertible preferred stock for gross proceeds of approximately $22 million, including the conversion of approximately $4 million of outstanding convertible promissory notes. Proceeds from the financing will be used to support the continued clinical development of its lead product, Gelesis100, as well as advancing its pipeline product, Gelesis 200, into the clinic.
 
“We’re pleased to receive this new round of financing to advance our products towards commercialization,”  said Yishai Zohar, Founder and Chief Executive Officer of Gelesis, “We appreciate the support from our new and existing investors in our mission to address the growing obesity and diabetes epidemics.”
 
In the first quarter, Gelesis added three leading experts in the treatment of obesity and its related comorbidities to its Scientific Advisory Board (SAB): Louis J. Aronne, MD, FACP, the Sanford I. Weill Professor of Metabolic Research at Weill-Cornell Medical College, Ken Fujioka, MD, Director of the Nutrition and Metabolic Research Center and the Center for Weight Management at the Scripps Clinic, and Angelo Tremblay, PhD, Professor in the Department of Social and Preventive Medicine at Laval University in Quebec City.
 
Gelesis also announced the appointment of two new directors, Meghan Fitzgerald and Robert Forrester, who bring additional commercialization and finance expertise to its Board. Ms. Fitzgerald is the EVP of Strategy, M&A, and Health Policy and an Executive Committee Member at Cardinal Health, a Fortune 22 company. She has previously held senior positions at Medco Health Solutions, Inc., Pfizer Global Pharmaceuticals, Merck and Sanofi. Mr. Forrester is the CEO of Verastem (NASDAQ: VSTM), and brings to the board 14 years of experience as CEO, COO, and CFO at both private and public life sciences companies, including Forma Therapeutics, CombinatoRx and Coley (acquired by Pfizer). 
 
Source: Gelesis100

Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE